Articles tagged "Hepatocellular carcinoma"

2019 American Transplant Congress
Development and Characterization of Human-Derived Xenograft Model for Hepatocellular Carcinoma
M. Nazzal¹, R. Steele², R. Ray³, N. Phillips², J. Long⁴, R. Ray²
¹Surgery, Saint Louis University, Saint Louis, MO, ²Pathology, Saint Louis University, Saint Louis, MO, ³Internal Medicine, Saint Louis University, Saint Louis, MO, ⁴Comparative Medicine, Saint Louis University, Saint Louis, MO
*Purpose: Hepatocellular carcinoma (HCC) is rising in the USA and treatment options are limited. There is no convenient animal model for HCC to study novel…
2019 American Transplant Congress
Long Term Impact of Intraoperative Autologous Blood Transfusion on HCC Recurrence in Liver Transplantation
G. Kelly¹, J. L. Pasko¹, E. Dewey², E. Maynard¹, S. L. Orloff¹, C. Enestvedt¹
¹Division of Abdominal Transplant, OHSU, Portland, OR, ²Department of General Surgery, OHSU, Portland, OR
*Purpose: The aim of this study was to determine whether intraoperative autologous transfusion in liver transplant patients with HCC affects the rate of recurrence.*Methods: We…
2018 American Transplant Congress
Tregs Expression Predicts Prognosis in Patients with Hepatocellular Carcinoma
A. Baquerizo,¹ V. Vavinskaya,² C. Frenette,¹ M. Nelson,¹ R. Schaffer,¹ J. Fisher,¹ L. Sher,³ B. Madani,¹ P. Pockros,¹ C. Marsh.¹
¹Surgery / Transplant, Scripps Green Hospital, La Jolla, CA; ²Pathology, UCSD, San Diego, CA; ³Surgery / Transplant, USC, Los Angeles, CA.
New therapeutic strategies are needed to improve the survival of patients with hepatocellular carcinoma (HCC), the third in overall global cancer-related mortality. T regulatory cells…
2018 American Transplant Congress
Utility of Combining Stereotactic Body Radiation Therapy (SBRT) to Transarterial Chemoembolization as Destination Therapy for Hepatocellular Cancer (HCC) within Milan Criteria
A. Murali, K. Soota, M. Karwal, T. Tanaka, J. Dunkelberg, M. Voigt.
University of Iowa Hospitals and Clinics, Iowa City.
Limited data are available on the effect of SBRT in patients with HCC within Milan. We aimed to compare TACE followed by SBRT with TACE…
2018 American Transplant Congress
Radiation Exposure to the Transplant Surgeon: A Case Study of Recent Yttrium-90 Treatment in an Explanted Liver
M. Decoteau,¹ P. Lewis,¹ S. Steuterman,² R. Schaffer,¹ J. Fisher,¹ J. Case,¹ C. Marsh.¹
¹Organ Transplantation, Scripps Green Hospital, La Jolla, CA; ²Medical Physics & Radiation Safety, Scripps Green Hospital, La Jolla, CA.
BACKGROUND: Yttrium-90 (Y-90) radioembolization for the treatment of hepatocellular carcinoma can present safety challenges to the surgeon when transplanting a recently treated Y-90 patient. To…
2018 American Transplant Congress
T Cell Lineage Imbalance and Regulatory Immune Populations in HCC Patients Undergoing Downstaging While Waitlisted for Liver Transplantation
P. Thevenot,¹ K. Nunez,¹ T. Sandow,² J. Gimenez,² J. Gonzalez-Rosario,¹ M. Patel,¹ A. Alfadhli,¹ D. Wyczechowska,³ A. Cohen.¹
¹Institute of Translational Research, Ochsner Health System, New Orleans, LA; ²Interventional Radiology, Ochsner Health System, New Orleans, LA; ³Stanley S Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA.
Purpose:In this study, we monitored peripheral lymphocyte lineage and regulatory immune populations in HCC patients undergoing DEB-TACE as a bridge to liver transplantation.Methods: Liver transplant…
2018 American Transplant Congress
Impact of Mammalian Target of Rapamycin Inhibitors on Hepatocellular Carcinoma Recurrence after Liver Transplant
N. Hendon,¹ D. Salerno,¹ C. Sammons,¹ K. Halazun.²
¹Pharmacy, NewYork-Presbyterian Hospital, New York, NY; ²Surgery, Weill Cornell Medical College, New York, NY.
Despite limited benefit to patients within Milan criteria on explant, mTORi are routinely utilized for prevention of hepatocellular carcinoma (HCC) recurrence after liver transplantation (LT).…
2018 American Transplant Congress
Liver Transplantation for Patients with Hepatocellular Carcinoma Presenting beyond Milan Criteria: Analysis of 789 Patients from the US Multicenter HCC Transplant Consortium
V. Agopian, United States Multicenter HCC Transplant Consortium.
UCLA, LA.
Objective: OPTN has recently approved MELD prioritization for HCC patients beyond Milan Criteria (MC) who are downstaged (DS) with locoregional therapy (LRT) prior to liver…
2018 American Transplant Congress
Liver Transplantation for Hepatocellular Carcinoma Outperform Other Populations in the New Hepatitis C Era
A. Alsina,¹ A. Athienitis,² J. Buggs,¹ E. Fallon,³ E. Parkinson,³ C. Albers,³ N. Kemmer.³
¹Transplantation Surgery, Tampa General Hospital, Tampa, FL; ²Muma College of Business, University of South Florida, Tamoa, FL; ³Transplant Hepatology, Tampa General Hospital, Tampa, FL.
Background: Long term results of HCC liver transplants (LTx) in the recent era of direct-acting antivirals (DAA) against hepatitis C (HCV) are not available. We…
2018 American Transplant Congress
Improving Prognostication amongst Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma: An International, 16-Center Study to Validate and Recalibrate HALTHCC
D. Firl,¹ K. Sasaki,¹ S. Kimura,² W. Dumronggittigule,³ A. Gorgen,⁴ J. Lerut,⁵ M. Rossi,⁶ U. Cillo,⁷ A. Viveiros,⁸ E. Tsochatzis,⁹ G. Otto,¹⁰ G. Ettorre,¹¹ G. Tisone,¹² M. Vivarelli,¹³ S. Agnes,¹⁴ J. Markmann,² T. Ikegami,¹⁵ T. Kaido,¹⁶ G. Sapisochin,⁴ V. Agopian,³ Q. Lai,^5,6 F. Aucejo.¹
¹CCF, Cleveland; ²MGH, Boston; ³UCLA, LA; ⁴UHN, Toronto, Canada; ⁵SLH, Louvain, Belgium; ⁶UH, Rome, Italy; ⁷UP, Padua, Italy; ⁸MUI, Innsbruck, Austria; ⁹UCL, London, United Kingdom; ¹⁰UM, Mainz, Germany; ¹¹SCH, Rome, Italy; ¹²TVU, Rome, Italy; ¹³AOU, Torrette Ancona, Italy; ¹⁴AGH, Rome, Italy; ¹⁵KU, Kyoto, Japan; ¹⁶KU, Kyushu, Japan.
Objective: Prognosticating outcomes in liver transplant (LT) for hepatocellular carcinoma (HCC) continues to challenge the field. Whereas adoption of the binary Milan Criteria (MC) generalized…